-
1
-
-
84924271853
-
Global cancer statistics, 2012
-
1 Torre, L.A., Bray, F., Siegel, R.L., et al. Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
-
(2015)
CA Cancer J Clin
, vol.65
, pp. 87-108
-
-
Torre, L.A.1
Bray, F.2
Siegel, R.L.3
-
2
-
-
84943797330
-
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
-
2 Chi, K., Hotte, S.J., Joshua, A.M., et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 26 (2015), 2044–2056.
-
(2015)
Ann Oncol
, vol.26
, pp. 2044-2056
-
-
Chi, K.1
Hotte, S.J.2
Joshua, A.M.3
-
3
-
-
84901231924
-
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel
-
3 Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 50 (2014), 1617–1627.
-
(2014)
Eur J Cancer
, vol.50
, pp. 1617-1627
-
-
Fitzpatrick, J.M.1
Bellmunt, J.2
Fizazi, K.3
-
4
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
4 Tannock, I.F., de Wit, R., Berry, W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
-
(2004)
N Engl J Med
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
-
5
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
5 Petrylak, D.P., Tangen, C.M., Hussain, M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004), 1513–1520.
-
(2004)
N Engl J Med
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
-
6
-
-
84866948935
-
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
-
6 Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
-
(2012)
Lancet Oncol
, vol.13
, pp. 983-992
-
-
Fizazi, K.1
Scher, H.I.2
Molina, A.3
-
7
-
-
84921846878
-
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
-
7 Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
-
(2015)
Lancet Oncol
, vol.16
, pp. 152-160
-
-
Ryan, C.J.1
Smith, M.R.2
Fizazi, K.3
-
8
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
8 Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
-
(2012)
N Engl J Med
, vol.367
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
-
9
-
-
84904871070
-
Enzalutamide in metastatic prostate cancer before chemotherapy
-
9 Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
-
(2014)
N Engl J Med
, vol.371
, pp. 424-433
-
-
Beer, T.M.1
Armstrong, A.J.2
Rathkopf, D.E.3
-
10
-
-
84922516195
-
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy
-
10 Satoh, T., Uemura, H., Tanabe, K., et al. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol 44 (2014), 1206–1215.
-
(2014)
Jpn J Clin Oncol
, vol.44
, pp. 1206-1215
-
-
Satoh, T.1
Uemura, H.2
Tanabe, K.3
-
11
-
-
84922527136
-
A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study)
-
11 Matsubara, N., Uemura, H., Satoh, T., et al. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol 44 (2014), 1216–1226.
-
(2014)
Jpn J Clin Oncol
, vol.44
, pp. 1216-1226
-
-
Matsubara, N.1
Uemura, H.2
Satoh, T.3
-
12
-
-
84973411823
-
Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer
-
12 Yamasaki, M., Yuasa, T., Yamamoto, S., et al. Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer. Anticancer Res 36 (2016), 361–365.
-
(2016)
Anticancer Res
, vol.36
, pp. 361-365
-
-
Yamasaki, M.1
Yuasa, T.2
Yamamoto, S.3
-
13
-
-
44449147748
-
Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan
-
13 Naito, S., Tsukamoto, T., Koga, H., et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38 (2008), 365–372.
-
(2008)
Jpn J Clin Oncol
, vol.38
, pp. 365-372
-
-
Naito, S.1
Tsukamoto, T.2
Koga, H.3
-
14
-
-
84942988298
-
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
-
14 Nozawa, M., Mukai, H., Takahashi, S., et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 20 (2015), 1026–1034.
-
(2015)
Int J Clin Oncol
, vol.20
, pp. 1026-1034
-
-
Nozawa, M.1
Mukai, H.2
Takahashi, S.3
-
15
-
-
41949104346
-
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
-
15 Scher, H.I., Halabi, S., Tannock, I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008), 1148–1159.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1148-1159
-
-
Scher, H.I.1
Halabi, S.2
Tannock, I.3
-
16
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
16 Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
17
-
-
84919338396
-
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer
-
17 Auchus, R.J., Yu, M.K., Nguyen, S., et al. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 19 (2014), 1231–1240.
-
(2014)
Oncologist
, vol.19
, pp. 1231-1240
-
-
Auchus, R.J.1
Yu, M.K.2
Nguyen, S.3
-
18
-
-
84922248732
-
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status
-
18 Azad, A.A., Eigl, B.J., Leibowitz-Amit, R., et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 67 (2015), 441–447.
-
(2015)
Eur Urol
, vol.67
, pp. 441-447
-
-
Azad, A.A.1
Eigl, B.J.2
Leibowitz-Amit, R.3
-
19
-
-
84924328268
-
Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
-
19 Nadal, R., Zhang, Z., Rahman, H., et al. Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 74 (2014), 1560–1568.
-
(2014)
Prostate
, vol.74
, pp. 1560-1568
-
-
Nadal, R.1
Zhang, Z.2
Rahman, H.3
-
20
-
-
84902077478
-
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone
-
20 Ravi, P., Mateo, J., Lorente, D., et al. External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. Eur Urol 66 (2014), 8–11.
-
(2014)
Eur Urol
, vol.66
, pp. 8-11
-
-
Ravi, P.1
Mateo, J.2
Lorente, D.3
|